Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP199887.RAn4xRTO9K_GHEgDgYri_95CeFQtcoC6PH2rLUmi1VOhQ130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP199887.RAn4xRTO9K_GHEgDgYri_95CeFQtcoC6PH2rLUmi1VOhQ130_provenance.
• NP301335.RA92Utk27S6rLBWncr3RKOJPcpjGJUYARwx3eJwFyeRIU130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP301335.RA92Utk27S6rLBWncr3RKOJPcpjGJUYARwx3eJwFyeRIU130_provenance.
• NP67741.RACojm4AheNFsHL7yEzQu7VOpeROpCn-aL09CLYdnMbo8130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP67741.RACojm4AheNFsHL7yEzQu7VOpeROpCn-aL09CLYdnMbo8130_provenance.
• NP217456.RA6-tWftWAe5ba94uHJMWB1h990VxeuQWExArh-raXkkI130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217456.RA6-tWftWAe5ba94uHJMWB1h990VxeuQWExArh-raXkkI130_provenance.
• NP217763.RA05uNQD0qJULlZQhz9acveUs7bFav_rWPWNlZSpAEv-g130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217763.RA05uNQD0qJULlZQhz9acveUs7bFav_rWPWNlZSpAEv-g130_provenance.
• NP944472.RA0S87m1-DhJ1nePywqZ25Cqjea8qsMjt-6daAfEdN6pY130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP944472.RA0S87m1-DhJ1nePywqZ25Cqjea8qsMjt-6daAfEdN6pY130_provenance.
• NP944551.RAzfw7cYj76Tlm2xZS_Azi2k9be0AGZKB4KBDf0iLwnf8130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP944551.RAzfw7cYj76Tlm2xZS_Azi2k9be0AGZKB4KBDf0iLwnf8130_provenance.
• NP951054.RA6U4kGzxc78NUYBUP6XW-0efAQ_nRY-27PAsuv1L9qpQ130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP951054.RA6U4kGzxc78NUYBUP6XW-0efAQ_nRY-27PAsuv1L9qpQ130_provenance.
• NP951271.RAwoGepfCiXnHF2e3GTN_WNcsNtYSWbmuS2D6g-crVenQ130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP951271.RAwoGepfCiXnHF2e3GTN_WNcsNtYSWbmuS2D6g-crVenQ130_provenance.
• NP951358.RAWuDoVw1bHdOeU7TVIR5GnLlz1h5qsN15qXT1Jsoh-ac130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP951358.RAWuDoVw1bHdOeU7TVIR5GnLlz1h5qsN15qXT1Jsoh-ac130_provenance.
• NP830522.RA9G_iPtlban8Nyqeu1FP00GgZH0e_-W4SBfENFQw7No0130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP830522.RA9G_iPtlban8Nyqeu1FP00GgZH0e_-W4SBfENFQw7No0130_provenance.
• NP830528.RA81XJ7M71R0IISPbDZS4B7vZZqDij9YXbzVCo_3QCxEY130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP830528.RA81XJ7M71R0IISPbDZS4B7vZZqDij9YXbzVCo_3QCxEY130_provenance.
• NP830515.RAUDwupbAuH-JqTmjHr8AZxnn3Z5fu9C8zumT3xFEQeOY130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP830515.RAUDwupbAuH-JqTmjHr8AZxnn3Z5fu9C8zumT3xFEQeOY130_provenance.
• NP830516.RARrzoQe6MrBDFI5TdJ2gKa5sj1j6ewfGYBLd9esH2DWY130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP830516.RARrzoQe6MrBDFI5TdJ2gKa5sj1j6ewfGYBLd9esH2DWY130_provenance.
• NP830519.RARe4Z0cZNykyjCvpw_GkljySQHRBe9g93yBkoqxR7mVI130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP830519.RARe4Z0cZNykyjCvpw_GkljySQHRBe9g93yBkoqxR7mVI130_provenance.
• NP217682.RAs8ZJhZ6WEImMqg0OCR5BcRNYTZL_u5BwYSg8tLjkx5E130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP217682.RAs8ZJhZ6WEImMqg0OCR5BcRNYTZL_u5BwYSg8tLjkx5E130_provenance.
• NP830520.RANiRx7P-Xp3et-uBitWKRiWC9P_5EaN5IGPhQPgHQ5vQ130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP830520.RANiRx7P-Xp3et-uBitWKRiWC9P_5EaN5IGPhQPgHQ5vQ130_provenance.
• NP830521.RAKP10VKlJU4dt1wbQ76YEsB4oqJBGqYxuc7tQtH2qQ9w130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP830521.RAKP10VKlJU4dt1wbQ76YEsB4oqJBGqYxuc7tQtH2qQ9w130_provenance.
• NP830527.RALeP5y4R2a0ciBBRI5JPYmlEDvk8qhLt7bKRarxHHmoA130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP830527.RALeP5y4R2a0ciBBRI5JPYmlEDvk8qhLt7bKRarxHHmoA130_provenance.
• NP830529.RAqpg8Fk1xBJEBjWJ_ZbSD0qoDW2bhHPNDBHOtn6COK4E130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP830529.RAqpg8Fk1xBJEBjWJ_ZbSD0qoDW2bhHPNDBHOtn6COK4E130_provenance.
• NP944263.RAjvg2a8s_nVRLkNjM45yKpvlpmrfZfQ5419aaX5S9BN8130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP944263.RAjvg2a8s_nVRLkNjM45yKpvlpmrfZfQ5419aaX5S9BN8130_provenance.
• NP183122.RAnKqdq9R8cMXZiKOA0gumAWiEoY0JSM0zPt7V1qDPGtg130_assertion description "[The combined effect of CYP1B1*3 polymorphism and NAT2 slow acetylator genotype contributed to an increased risk for breast cancer in patients in this study (p=0.004).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP183122.RAnKqdq9R8cMXZiKOA0gumAWiEoY0JSM0zPt7V1qDPGtg130_provenance.